Hikma appoints Dr Shahin Fesharaki as Chief Scientific Officer and Global Head of R&D

London, 5 August 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, today announces that Dr Shahin Fesharaki joins the company as Chief Scientific Officer and Global Head of Research & Development (R&D). Dr Fesharaki will have responsibility for all aspects of the company’s R&D and becomes a member of Hikma’s Executive Committee, reporting into the CEO, Siggi Olafsson.

Press Release Corporate 5 August 2019

“Shahin has a great industry track record of developing and commercialising hundreds of new products including Abbreviated New Drug Applications (ANDAs), first-to-file and first-to-market opportunities,” said Siggi Olafsson, Chief Executive Officer of Hikma.  “Filling our pipeline with products needed by our customers and patients is a key aspect of our strategy, and the appointment of Shahin is a significant step forward in successfully delivering on this strategy.”

Dr Fesharaki brings more than 25 years of extensive development experience in both generic and branded pharmaceuticals across a broad range of technologies and dosage forms. He has held senior R&D leadership positions at some of the most successful generic pharmaceutical companies including Watson, Apotex and more recently Actavis where he led the global R&D operations function. 

“I’m proud to be joining the Hikma team at such a pivotal time in the company’s growth journey,” said Dr Fesharaki.  “Hikma’s commitment to quality is one that I share, and I am eager to join the team and lead the R&D function forward with new and needed products that will benefit patients around the world.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.